 | • レポートコード：MRC2304A119 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、223ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に1,211.14百万ドルであった世界の脊髄性筋萎縮症（SMA）治療市場規模が2022年に1,394.26百万ドルに到達し、2027年までにCAGR 15.29％で成長して2,845.08百万ドルへと拡大すると予測しています。当調査資料では、脊髄性筋萎縮症（SMA）治療の世界市場について多角的な視点から分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（タイプ1、タイプ2、タイプ3、タイプ4）分析、治療別（薬物療法、遺伝子補充療法）分析、投与経路別（髄腔内投与、経口投与）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめました。なお、当書内の企業情報としては、Astellas Pharma Inc.、AstraZeneca PLC、Biogen Inc.、Boehringer Ingelheim GmbH、Catalyst Pharmaceuticals、Chugai Pharmaceutical、Cure SMA、Cytokinetics, Inc.、F. Hoffmann-La Roche AG、Genentech, Inc、Genzyme Corporation、Ionis Pharmaceuticals, Inc.などが掲載されています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の脊髄性筋萎縮症（SMA）治療市場規模：種類別 - タイプ1の市場規模 - タイプ2の市場規模 - タイプ3の市場規模 - タイプ4の市場規模 ・世界の脊髄性筋萎縮症（SMA）治療市場規模：治療別 - 薬物療法の市場規模 - 遺伝子補充療法の市場規模 ・世界の脊髄性筋萎縮症（SMA）治療市場規模：投与経路別 - 髄腔内投与の市場規模 - 経口投与の市場規模 ・世界の脊髄性筋萎縮症（SMA）治療市場規模：地域別 - 南北アメリカの脊髄性筋萎縮症（SMA）治療市場規模 アメリカの脊髄性筋萎縮症（SMA）治療市場規模 カナダの脊髄性筋萎縮症（SMA）治療市場規模 ブラジルの脊髄性筋萎縮症（SMA）治療市場規模 ... - アジア太平洋の脊髄性筋萎縮症（SMA）治療市場規模 日本の脊髄性筋萎縮症（SMA）治療市場規模 中国の脊髄性筋萎縮症（SMA）治療市場規模 インドの脊髄性筋萎縮症（SMA）治療市場規模 韓国の脊髄性筋萎縮症（SMA）治療市場規模 台湾の脊髄性筋萎縮症（SMA）治療市場規模 ... - ヨーロッパ/中東/アフリカの脊髄性筋萎縮症（SMA）治療市場規模 イギリスの脊髄性筋萎縮症（SMA）治療市場規模 ドイツの脊髄性筋萎縮症（SMA）治療市場規模 フランスの脊髄性筋萎縮症（SMA）治療市場規模 ロシアの脊髄性筋萎縮症（SMA）治療市場規模 ... - その他地域の脊髄性筋萎縮症（SMA）治療市場規模 ・競争状況 ・企業情報 |
The Global Spinal Muscular Atrophy Treatment Market size was estimated at USD 1,211.14 million in 2021 and expected to reach USD 1,394.26 million in 2022, and is projected to grow at a CAGR 15.29% to reach USD 2,845.08 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Spinal Muscular Atrophy Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Type 1, Type 2, Type 3, and Type 4.
Based on Treatment, the market was studied across Drug Therapy and Gene Replacement Therapy.
Based on Route of Administration, the market was studied across Intrathecal and Oral.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Spinal Muscular Atrophy Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Spinal Muscular Atrophy Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Spinal Muscular Atrophy Treatment Market, including Astellas Pharma Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Catalyst Pharmaceuticals, Chugai Pharmaceutical, Cure SMA, Cytokinetics, Inc., F. Hoffmann-La Roche AG, Genentech, Inc, Genzyme Corporation, Ionis Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Natera, Inc, Novartis International AG, Novo Nordisk A/S, PerkinElmer, Inc., Pfizer Inc., PTC Therapeutics, Regeneron Pharmaceuticals, Inc., Salarius Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and UW Health.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Spinal Muscular Atrophy Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Spinal Muscular Atrophy Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Spinal Muscular Atrophy Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Spinal Muscular Atrophy Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Spinal Muscular Atrophy Treatment Market?
6. What is the market share of the leading vendors in the Global Spinal Muscular Atrophy Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Spinal Muscular Atrophy Treatment Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising burden of spinal muscular atrophy
5.1.1.2. R&D initiatives for the potential treatment by companies
5.1.1.3. Awareness programs initiatives by government and nonprofit organizations
5.1.2. Restraints
5.1.2.1. Limited time-window for successful therapy delivery
5.1.3. Opportunities
5.1.3.1. Joint development programs by market players
5.1.3.2. Expansion of distribution channels particularly in developing countries
5.1.4. Challenges
5.1.4.1. Limited access for the treatment of SMA
5.2. Cumulative Impact of COVID-19
6. Spinal Muscular Atrophy Treatment Market, by Type
6.1. Introduction
6.2. Type 1
6.3. Type 2
6.4. Type 3
6.5. Type 4
7. Spinal Muscular Atrophy Treatment Market, by Treatment
7.1. Introduction
7.2. Drug Therapy
7.3. Gene Replacement Therapy
8. Spinal Muscular Atrophy Treatment Market, by Route of Administration
8.1. Introduction
8.2. Intrathecal
8.3. Oral
9. Americas Spinal Muscular Atrophy Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Spinal Muscular Atrophy Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Spinal Muscular Atrophy Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Astellas Pharma Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AstraZeneca PLC
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Biogen Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Boehringer Ingelheim GmbH
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Catalyst Pharmaceuticals
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Chugai Pharmaceutical
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Cure SMA
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Cytokinetics, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. F. Hoffmann-La Roche AG
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Genentech, Inc
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Genzyme Corporation
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Ionis Pharmaceuticals, Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Isis Pharmaceuticals, Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Natera, Inc
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Novartis International AG
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Novo Nordisk A/S
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. PerkinElmer, Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Pfizer Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. PTC Therapeutics
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Regeneron Pharmaceuticals, Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Salarius Pharmaceuticals, Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Takeda Pharmaceutical Company Limited
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. UW Health
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing